Eesti - eesti - Ravimiamet

auxilia pharma oÜ - rivaroksabaan - õhukese polümeerikattega tablett - 10mg 45tk; 10mg 30tk; 10mg 20tk; 10mg 50tk; 10mg 15tk; 10mg 42tk; 10mg 56tk; 10mg 10tk; 10mg 98tk; 10mg 5tk

Eesti - eesti - Ravimiamet

viatris limited - apiksabaan - õhukese polümeerikattega tablett - 5mg 1000tk; 5mg 20tk; 5mg 100tk; 5mg 200tk; 5mg 60tk; 5mg 180tk; 5mg 168tk; 5mg 14tk; 5mg 56tk

Eesti - eesti - Ravimiamet

auxilia pharma oÜ - rivaroksabaan - õhukese polümeerikattega tablett - 15mg 20tk; 15mg 5tk; 15mg 90tk; 15mg 50tk; 15mg 56tk; 15mg 45tk; 15mg 10tk; 15mg 42tk; 15mg 100tk

Eesti - eesti - Ravimiamet

auxilia pharma oÜ - rivaroksabaan - õhukese polümeerikattega tablett - 20mg 56tk; 20mg 50tk; 20mg 100tk; 20mg 30tk; 20mg 90tk; 20mg 10tk

Eesti - eesti - Ravimiamet

auxilia pharma oÜ - rivaroksabaan - õhukese polümeerikattega tablett - 2,5mg 50tk; 2,5mg 15tk; 2,5mg 98tk; 2,5mg 28tk; 2,5mg 42tk; 2,5mg 30tk; 2,5mg 45tk; 2,5mg 10tk

Eesti - eesti - Ravimiamet

viatris limited - apiksabaan - õhukese polümeerikattega tablett - 5mg 120tk; 5mg 200tk; 5mg 28tk; 5mg 180tk; 5mg 100tk; 5mg 1000tk; 5mg 20tk; 5mg 56tk

Eesti - eesti - Ravimiamet

viatris limited - apiksabaan - õhukese polümeerikattega tablett - 2,5mg 200tk; 2,5mg 56tk; 2,5mg 100tk; 2,5mg 60tk; 2,5mg 180tk; 2,5mg 20tk; 2,5mg 10tk; 2,5mg 1000tk

Eesti - eesti - Ravimiamet

sandoz pharmaceuticals d.d. - apiksabaan - õhukese polümeerikattega tablett - 5mg 10tk; 5mg 28tk; 5mg 30tk; 5mg 12tk; 5mg 168tk; 5mg 14tk; 5mg 200tk; 5mg 180tk; 5mg 20tk; 5mg 60tk; 5mg 100tk

Eesti - eesti - Ravimiamet

sandoz pharmaceuticals d.d. - apiksabaan - õhukese polümeerikattega tablett - 2,5mg 200tk; 2,5mg 14tk; 2,5mg 10tk; 2,5mg 180tk; 2,5mg 20tk; 2,5mg 56tk; 2,5mg 60tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

mylan ireland limited - rivaroksabaan - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - antitrombootilised ained - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers.  rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events.  ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.  treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult   patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.